Octreotide improves human lymphatic fluid transport a translational trial

What Was Tested

This randomized controlled trial paper looks at Octreotide.

In this cross-over study, the researchers explore the direct effect of octreotide on human lymphatic drainage.

Near-infrared fluorescence imaging was used to examine spontaneous lymphatic contractions and lymph pressure in peripheral lymphatic vessels and plethysmography was performed to assess the capillary filtration rate, capillary filtration coefficient and isovolumetric pressures of the lower leg.

Who Took Part

The study group was 16 adults.

The age groups tagged for this paper are adults.

Clinical: in a double-blinded, randomized, cross-over trial including 16 healthy adults, the researchers administered either octreotide or saline as an intravenous infusion for 2.5 h.

How the Study Was Run

The researchers set it up as a randomized, double-blind and crossover study.

The adults were allocated by chance, so the Octreotide group and the comparison group should start out alike.

As a double-blind Octreotide study, the assignments were hidden from both participants and investigators until the end.

Each person switched between Octreotide and the comparison at some point, usually with a gap in between.

Pre-clinical: the effect of octreotide on force generation was assessed during acute and prolonged drug incubation on human lymphatic vessels mounted in a myograph.

What Was Measured

The subject headings attached to it are Octreotide, Chylothorax, Gastrointestinal Agents and Lymphatic Vessels.

Author keywords: Clinical study, Near-infrared fluorescence imaging and Randomized cross-over study.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of Octreotide in 16 adults.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2024 (European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery), a journal based in Germany.

More context: the Octreotide compound page, all human trials.